PURPOSE: We assessed the prognostic impact of @entity5 and @entity1 characteristics, and therapy. MATERIALS AND METHODS: We retrospectively reviewed the records of 180 @entity1 with @entity4153 in which @entity1 and @entity5 characteristics, therapy, followup duration and survival status had been documented. @entity1 age, sex, primary site, histological features, @entity5 size, stage, locoregional therapy, systemic chemotherapy and hormonal manipulations were analyzed for association with survival. RESULTS: There were 106 cases of bladder, 60 prostatic, 8 renal and 6 @entity4153 . Median survival was 10.5 months overall, and 7 and 13 months for prostatic and @entity150 , respectively (p <0.0001 log rank analysis). In all cases metastatic disease at presentation (p <0.008, risk ratio 1.9) predicted poor survival on multivariate analysis. Radical surgery (p <0.0001, risk ratio 0.34) and @entity900 chemotherapy (p <0.0001, risk ratio 0.20) were the only factors that predicted improved survival on multivariate analysis. For @entity263 primary surgical therapy (p <0.012, risk ratio 0.46) was the only parameter that predicted survival on univariate analysis. For @entity150 only @entity900 chemotherapy (p <0.0001, risk ratio 0.15) predicted survival on multivariate analysis. CONCLUSIONS: @entity4153 has a poor prognosis, which is worse in prostatic than @entity1494 . @entity1 and @entity5 characteristics were not determinants of survival when prostatic and @entity150 were analyzed individually. For @entity4623 only primary surgical therapy was associated with prolonged survival, while for @entity1494 @entity900 chemotherapy was associated with a favorable prognosis. We recommend considering primary surgical therapy for prostatic and @entity900 based chemotherapy for @entity150 .

XXXX : determination of clinical and therapeutic factors associated with survival.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'Patient'] @entity263 :: ('MESH:D011471', 'Disease') :: ['prostatic small cell carcinoma'] @entity4153 :: ('MESH:D018288', 'Disease') :: ['Genitourinary small cell carcinoma', 'ureteral small cell carcinoma', 'genitourinary small cell carcinoma'] @entity1494 :: ('MESH:D001745', 'Disease') :: ['bladder disease'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'genitourinary small cell carcinoma tumor'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity150 :: ('MESH:D001749', 'Disease') :: ['bladder small cell carcinoma'] @entity4623 :: ('MESH:D011469', 'Disease') :: ['prostatic disease']
@entity4153 :: (MESH:D018288,Disease) :: ['Genitourinary small cell carcinoma']
